HomeCompareMXCHF vs MRK

MXCHF vs MRK: Dividend Comparison 2026

MXCHF yields 7.14% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $36.8K in total portfolio value
10 years
MXCHF
MXCHF
● Live price
7.14%
Share price
$1.12
Annual div
$0.08
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.9K
Annual income
$0.74
Full MXCHF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — MXCHF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMXCHFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MXCHF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MXCHF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MXCHF
Annual income on $10K today (after 15% tax)
$607.14/yr
After 10yr DRIP, annual income (after tax)
$0.63/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,596.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MXCHF + MRK for your $10,000?

MXCHF: 50%MRK: 50%
100% MRK50/50100% MXCHF
Portfolio after 10yr
$39.3K
Annual income
$5,057.26/yr
Blended yield
12.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MXCHF
No analyst data
Altman Z
1.2
Piotroski
5/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MXCHF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMXCHFMRK
Forward yield7.14%2.81%
Annual dividend / share$0.08$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%32.7%
Portfolio after 10y$20.9K$57.7K
Annual income after 10y$0.74$10,113.78
Total dividends collected$729.00$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MXCHF vs MRK ($10,000, DRIP)

YearMXCHF PortfolioMXCHF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,057$357.14$11,213$373.04$156.00MRK
2$12,016$184.53$12,667$512.06$651.00MRK
3$12,950$93.70$14,439$708.14$1.5KMRK
4$13,904$47.19$16,640$988.16$2.7KMRK
5$14,901$23.68$19,432$1,394.07$4.5KMRK
6$15,956$11.86$23,057$1,992.90$7.1KMRK
7$17,079$5.93$27,889$2,894.79$10.8KMRK
8$18,277$2.97$34,518$4,286.29$16.2KMRK
9$19,558$1.48$43,912$6,494.35$24.4KMRK
10$20,928$0.74$57,714$10,113.78$36.8KMRK

MXCHF vs MRK: Complete Analysis 2026

MXCHFStock

Orbia Advance Corporation, S.A.B. de C.V. provides products and solutions for precision agriculture, building and infrastructure, fluor, polymer, and data communications sectors worldwide. The company offers irrigation systems, digital agricultural technologies, and related services; and data communications infrastructure, including conduits, and cables and fiber optics, as well as pressurized pipes for natural gas and other solutions. It also provides pipes and fittings for water management systems, and home water heating and cooling systems; fluorinated material products, including chemical products, propellants, and advanced materials for a range of applications in the automotive, infrastructure, health and medicine, HVAC, and food cold chain industries; and general and special PVC resins, and other vinyl polymers for various applications. The company was formerly known as Mexichem, S.A.B. de C.V. and changed its name to Orbia Advance Corporation, S.A.B. de C.V. in August 2019. Orbia Advance Corporation, S.A.B. de C.V. was founded in 1953 and is headquartered in Mexico City, Mexico.

Full MXCHF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MXCHF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MXCHF vs SCHDMXCHF vs JEPIMXCHF vs OMXCHF vs KOMXCHF vs MAINMXCHF vs JNJMXCHF vs ABBVMXCHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.